{
  "abstract": "Background\n\nObesity is a recognized risk factor for renal cell carcinoma (RCC) incidence, but higher body mass index (BMI) measured at diagnosis has been paradoxically associated with improved survival. This study investigated whether postdiagnosis changes in BMI and metabolic comorbidities combined with BMI at diagnosis are associated with survival.Methods\n\nThis study examined 1289 patients with nonmetastatic RCC (stage I-III) from the Oncology Research Information Exchange Network. BMI was assessed at diagnosis and at 2 and 3 years postdiagnosis. Multivariable Cox regression and restricted cubic spline models estimated hazard ratios (HRs) for overall survival (OS) and disease-free survival (DFS).Results\n\nModest weight gain (<10%) and stability were most favorable trajectories. Compared with modest weight gain, postdiagnosis weight loss was associated with worse OS and DFS (>10% loss at 2 years: OS HR, 7.77; 95% CI, 3.00-20.16; DFS HR, 3.13; 95% CI, 1.68-5.82), independent of BMI at diagnosis, whereas substantial weight gain was associated with worse OS (>10% gain at 3 years: OS HR, 3.26; 95% CI, 1.14-9.32). Nonobese patients with diabetes had significantly worse DFS (HR, 1.83; 95% CI, 1.22-2.76), whereas the association between obesity and improved survival was mainly limited to patients without diabetes (HR, 0.75; 95% CI, 0.58-0.97).Conclusions\n\nPostdiagnosis weight trajectory and metabolic health are important prognostic factors for nonmetastatic RCC. Weight stability and absence of diabetes were associated with more favorable outcomes. Incorporating repeated BMI measurements and diabetes status may improve risk stratification during RCC survivorship.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.",
    "Department of Urology, Stanford University School of Medicine, Stanford, California, USA.",
    "Department of Epidemiology, Stanford University, Palo Alto, California, USA.",
    "Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.",
    "Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.",
    "Huntsman Cancer Institute, Salt Lake City, Utah, USA.",
    "H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.",
    "Department of Urology, Ohio State University, Columbus, Ohio, USA.",
    "University of Iowa, Holden Comprehensive Cancer Center, Iowa City, Iowa, USA.",
    "Division of Hematology/Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, USA.",
    "University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.",
    "Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.",
    "Norris Comprehensive Cancer Center and Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.",
    "Murtha Cancer Center, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.",
    "Stephenson Cancer Center, University of Oklahoma, Oklahoma City, Oklahoma, USA.",
    "Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.",
    "Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, USA.",
    "Aster Insights, Tampa, Florida, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 22,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Monica Sarker",
      "orcid": "0009-0000-4870-5067"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Zhengyi Deng"
    },
    {
      "affs": [
        3
      ],
      "name": "Eric C Kauffman"
    },
    {
      "affs": [
        0
      ],
      "name": "Li Tang"
    },
    {
      "affs": [
        4
      ],
      "name": "Marilyn L Kwan",
      "orcid": "0000-0001-8863-3950"
    },
    {
      "affs": [
        2
      ],
      "name": "Marvin E Langston"
    },
    {
      "affs": [
        5
      ],
      "name": "Sumati Gupta"
    },
    {
      "affs": [
        6
      ],
      "name": "G Daniel Grass",
      "orcid": "0000-0002-8417-5611"
    },
    {
      "affs": [
        7
      ],
      "name": "Eric A Singer"
    },
    {
      "affs": [
        8
      ],
      "name": "Yousef Zakharia"
    },
    {
      "affs": [
        9
      ],
      "name": "Paul V Viscuse",
      "orcid": "0000-0003-0834-8688"
    },
    {
      "affs": [
        10
      ],
      "name": "Laura Graham"
    },
    {
      "affs": [
        11
      ],
      "name": "Saum Ghodoussipour"
    },
    {
      "affs": [
        12
      ],
      "name": "Bodour Salhia"
    },
    {
      "affs": [
        13
      ],
      "name": "Sean Q Kern"
    },
    {
      "affs": [
        14
      ],
      "name": "Adanma Ayanambakkam"
    },
    {
      "affs": [
        15
      ],
      "name": "Zin Myint"
    },
    {
      "affs": [
        16
      ],
      "name": "Jennifer King"
    },
    {
      "affs": [
        16
      ],
      "name": "Seyi Oderinde"
    },
    {
      "affs": [
        17
      ],
      "name": "Michelle L Churchman"
    },
    {
      "affs": [
        17
      ],
      "name": "Robert J Rounbehler"
    },
    {
      "affs": [
        0
      ],
      "name": "Ken Batai"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7nhm523tfwx5n.bib",
  "cited_by": 0,
  "doi": "10.1002/cncr.70653",
  "fulltext_url": "https://europepmc.org/articles/PMC13693986",
  "id": "7nhm523tfwx5n",
  "issns": [
    "0008-543X",
    "1097-0142"
  ],
  "landing_url": "https://europepmc.org/article/MED/42913421",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Renal cell carcinoma treatment"
    ]
  ],
  "openalex": "W7223262004",
  "pdf_url": "https://europepmc.org/articles/PMC13693986?pdf=render",
  "pmcid": "PMC13693986",
  "pmid": "42913421",
  "published": "2026-10-30",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/7nhm523tfwx5n.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:03Z",
      "native_id": "MED:42913421",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42913421"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Renal cell carcinoma treatment",
      "subfield": "general"
    }
  ],
  "title": "Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients.",
  "title_text": "Body mass index at diagnosis, postdiagnosis change, and role of metabolic comorbidities in relation to survival in nonmetastatic renal cell carcinoma patients.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:03Z",
  "url": "https://research.draconitic.com/paper/7nhm523tfwx5n",
  "venue": "Cancer",
  "versions": []
}